ACT 389949

Drug Profile

ACT 389949

Alternative Names: ACT-389949

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Anti-inflammatories; Antidementias
  • Mechanism of Action FPR2 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Metabolic disorders

Most Recent Events

  • 01 May 2013 Actelion completes a phase I trial in Healthy volunteers in the UK (NCT02099201)
  • 01 Nov 2012 Phase-I clinical trials in Metabolic disorders (in volunteers) in United Kingdom (PO)
  • 01 May 2012 Actelion completes a phase I trial in Healthy volunteers in the Netherlands (NCT02099071)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top